retinai

Improve your Clinical Studies with **RetinAI Discovery**®

CHALLENGES

DELAYS & LOSS TO FOLLOW UP

Enrolling patients in a study may involve a third-party evaluation, **increasing onboarding time and risking a potential loss to follow up** between first visit and enrollment. Additionally, pivotal GO/NO GO decisions can be delayed due to the operational challenges of aggregating data from multiple sites.

A SIGNIFICANT INVESTMENT & RISK

Clinical studies are one of the largest expenses for pharma and life science companies and many risk **failure due to suboptimal study design or an inadequate definition of patient subgroups.**

SOLUTIONS

CENTRALIZING DATA COLLECTION

We offer a single web platform for data collection and analysis, **increasing visibility and monitoring** during the study developing and enabling stakeholders to make **real time decisions.**

REAL TIME EVALUATION OF ENROLLMENT CRITERIA & ENDPOINTS

Automatic expert-level measurements for retinal thickness (central subfield thickness) and fluid volume (intraretinal and sub-retinal fluid, pigment epithelium detachment) for **real time data analysis to support patient enrollment.**

ENABLING THE RIGHT DECISIONS SOONER

Discovery accelerates clinical studies by effectively managing data at scale from multiple vendors and data sources. The certified platform uses a **decentralized approach** for multi-modal image and data collection and management, empowering decision makers with **innovative AI tools for endpoint analysis and supporting patient assessment and enrollment.**

CONNECTED

Interoperability by default via a cloud-based web portal for collaborative analysis

INSIGHTFUL

Validated AI modules for multi-modal analysis and medical image management

CERTIFIED & SECURE

CE-Marked and GDPR-compliant platform ensuring privacy and security

ENABLING THE RIGHT DECISION SOONER IN HEALTHCARE

MONITORING STUDY PROGRESS ANYWHERE AT ANYTIME

Stakeholders with access to the platform can monitor enrollment, quality of data collected and overall study progress, saving time at every step.

SAME DAY PATIENT EVALUATION WORKFLOWS

The platform is used today in wet AMD and DME studies to assess treatment impact for new therapies via biomarkers like central macular thickness and fluid volumes. During the patient visit, images are uploaded to the platform and expert reviewers can assess images remotely, providing real-time feedback to the clinical site.

To learn more about RetinAI and our tools, please visit www.retinai.com to schedule a demo.